These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

595 related items for PubMed ID: 16867163

  • 21. Innovative insulins--where do analogues fit?
    Phillips LK, Phillips PJ.
    Aust Fam Physician; 2006 Dec; 35(12):969-73. PubMed ID: 17149471
    [Abstract] [Full Text] [Related]

  • 22. Insulin detemir (levemir), a new long-acting insulin.
    Med Lett Drugs Ther; 2006 Jul 03; 48(1238):54-5. PubMed ID: 16841022
    [Abstract] [Full Text] [Related]

  • 23. Improving treatment satisfaction and other patient-reported outcomes in people with type 2 diabetes: the role of once-daily insulin glargine.
    Bradley C, Gilbride CJ.
    Diabetes Obes Metab; 2008 Jul 03; 10 Suppl 2():50-65. PubMed ID: 18577157
    [Abstract] [Full Text] [Related]

  • 24. [My approach to the management of a type I diabetic treated with short-acting insulin analogue].
    Colombel A, Charbonnel B.
    Journ Annu Diabetol Hotel Dieu; 1999 Jul 03; ():165-77. PubMed ID: 10732416
    [No Abstract] [Full Text] [Related]

  • 25. Insulin glargine (Lantus), a new long-acting insulin.
    Med Lett Drugs Ther; 2001 Aug 06; 43(1110):65-6. PubMed ID: 11490321
    [No Abstract] [Full Text] [Related]

  • 26. PHARMAC and long-acting insulin analogues: a poor man's insulin pump--but not available to the poor man.
    Krebs J.
    N Z Med J; 2005 Aug 26; 118(1221):U1641. PubMed ID: 16138177
    [Abstract] [Full Text] [Related]

  • 27. Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes.
    Clements MR, Tits J, Kinsley BT, Råstam J, Friberg HH, Ligthelm RJ.
    Diabetes Obes Metab; 2008 Mar 26; 10(3):229-37. PubMed ID: 18269638
    [Abstract] [Full Text] [Related]

  • 28. A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes.
    Hassan K, Rodriguez LM, Johnson SE, Tadlock S, Heptulla RA.
    Pediatrics; 2008 Mar 26; 121(3):e466-72. PubMed ID: 18299307
    [Abstract] [Full Text] [Related]

  • 29. Insulin aspart: a review.
    Owens D, Vora J.
    Expert Opin Drug Metab Toxicol; 2006 Oct 26; 2(5):793-804. PubMed ID: 17014395
    [Abstract] [Full Text] [Related]

  • 30. In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine.
    Bruttomesso D, Crazzolara D, Maran A, Costa S, Dal Pos M, Girelli A, Lepore G, Aragona M, Iori E, Valentini U, Del Prato S, Tiengo A, Buhr A, Trevisan R, Baritussio A.
    Diabet Med; 2008 Mar 26; 25(3):326-32. PubMed ID: 18307459
    [Abstract] [Full Text] [Related]

  • 31. [Better blood sugar control in diabetics. Insulin glargin--a long-acting insulin analogue].
    Schubert-Zsilavecz M, Wurglics M.
    Pharm Unserer Zeit; 2001 Mar 26; 30(2):125-30. PubMed ID: 11279982
    [No Abstract] [Full Text] [Related]

  • 32. New insulins in the treatment of diabetes mellitus.
    Lindholm A.
    Best Pract Res Clin Gastroenterol; 2002 Jun 26; 16(3):475-92. PubMed ID: 12079270
    [Abstract] [Full Text] [Related]

  • 33. Early hypoglycaemia after accidental intramuscular injection of insulin glargine.
    Karges B, Boehm BO, Karges W.
    Diabet Med; 2005 Oct 26; 22(10):1444-5. PubMed ID: 16176210
    [Abstract] [Full Text] [Related]

  • 34. Insulin therapy and quality of life. A review.
    Pouwer F, Hermanns N.
    Diabetes Metab Res Rev; 2009 Sep 26; 25 Suppl 1():S4-S10. PubMed ID: 19662621
    [Abstract] [Full Text] [Related]

  • 35. Comparison of glycaemic control in patients with Type 2 diabetes on basal insulin and fixed combination oral antidiabetic treatment: results of a pilot study.
    De Mattia G, Laurenti O, Moretti A.
    Acta Diabetol; 2009 Mar 26; 46(1):67-73. PubMed ID: 19030772
    [Abstract] [Full Text] [Related]

  • 36. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections.
    Bode BW.
    Clin Ther; 2007 Mar 26; 29 Suppl D():S135-44. PubMed ID: 18191065
    [Abstract] [Full Text] [Related]

  • 37. Hypoglycemia rates with basal insulin analogs.
    Little S, Shaw J, Home P.
    Diabetes Technol Ther; 2011 Jun 26; 13 Suppl 1():S53-64. PubMed ID: 21668338
    [Abstract] [Full Text] [Related]

  • 38. Unlocking the opportunity of tight glycaemic control. Far from goal.
    Del Prato S.
    Diabetes Obes Metab; 2005 Nov 26; 7 Suppl 1():S1-4. PubMed ID: 16135133
    [Abstract] [Full Text] [Related]

  • 39. [The new insulins].
    Krzentowski G.
    Rev Med Brux; 2005 Sep 26; 26(4):S241-5. PubMed ID: 16240869
    [Abstract] [Full Text] [Related]

  • 40. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study.
    Hermansen K, Dornhorst A, Sreenan S.
    Curr Med Res Opin; 2009 Nov 26; 25(11):2601-8. PubMed ID: 19739940
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.